Cookies on Zenoot

This website uses cookies to ensure you get the best experience on our website. More info

3 minute read - 7th August 2023

£33m Kindeva investment to create and protect jobs

Kindeva Drug Delivery has received £33m of joint government and industry investment which will ensure a new generation of green, low-carbon, respiratory inhalers are made in the UK, supporting efforts to grow the economy.

The investment will create 40 full-time jobs and safeguard 218 existing full-time jobs across Kindeva’s sites in Clitheroe and Loughborough. Kindeva Drug Delivery is a global contract development and manufacturing organisation, specialising in pharmaceutical drug-device combination products, such as inhalers, nebulisers and medicated patches.

It is the sixth investment delivered through the Life Sciences Innovative Manufacturing Fund and its predecessor the Medicines and Diagnostics Manufacturing Transformation Fund, which has supported UK life sciences manufacturing with £340m in joint government and industry backing in the last financial year, and £416m since 2021.

Never miss the latest manufacturing news by signing up to our newsletter here

Investment totalling £33m with inhaler manufacturer Kindeva will support its UK production growth and help create and secure jobs / Picture: Getty/iStock

The government says this continues its commitment of helping the UK’s thriving life sciences sector to grow the economy and create well-paid jobs across the country.

George Freeman MP, minister of state for science, research & innovation, said: “Our £94 billion life science sector is one of our great industries – based on a deep long-term partnership between industry, investors, government, the NHS and disease charities – supporting us all to live healthier lives and providing over 250,000 high-skilled jobs in research and development clusters all around the UK.

“It is also driving billions of pounds worth of direct investment into the UK, something this government is determined to capitalise on through our global leadership via the Oxford Covid vaccine and NHS Recovery trial. The pace of new technology is transforming the sector and today’s investments signal our commitment to domestic manufacturing and skills enhancement, to deliver a robust future for UK life sciences that will not only play a key role in the country’s future economic success, but in improving our health as well.”

Kindeva’s global chief commercial officer, David Stevens, added: “This joint investment creates a myriad of new opportunities for colleagues within the UK, as significant technical and regulatory expertise is required in the development and manufacturing of complex inhalation pharmaceutical products.

“Furthermore, it provides Kindeva with a springboard to expand our capabilities and capacity, while simultaneously partnering with the largest pharmaceutical companies in the world to bring the next generation of green inhalers to market, with a common goal of safeguarding access to necessary therapies for our patients and also reducing our impact on the planet.”

The Kindeva funding follows on from the government’s £650m ‘Life Sci for Growth’ package announced in May this year, aimed at supporting the UK’s life sciences sector and helping to deliver the Science and Technology Framework through reforming regulation, boosting investment and driving up talent and skills.

This content is copyright of Zenoot Ltd and its originator. You can use extracts, share or link to this page and you may draw the attention of others to content posted on our site. Bulk copying of text is not permitted. You can view our Terms of Use here.